Disc Medicine (NASDAQ:IRON) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Key Points

• Disc Medicine reported a loss of ($1.65) EPS, missing the consensus by $0.03, and IRON shares traded down $0.58 to $67.06 on below-average volume following the release.
• There have been notable insider sales: CEO John D. Quisel sold 13,264 shares and COO Jonathan Yen‑Wen Yu sold 3,231 shares on Feb. 17, with insiders selling 59,410 shares over the last 90 days and currently owning 3.64% of the company.
• Analysts maintain a consensus "Moderate Buy" with a $104.80 target, despite mixed recent price‑target moves (examples include Morgan Stanley $75, Wedbush $88, and Stifel $110) and ratings split of ten Buys, one Hold and one Sell.

Disc Medicine (NASDAQ:IRON - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($1.65) earnings per share for the quarter, missing the consensus estimate of ($1.62) by ($0.03), FiscalAI reports.

Disc Medicine Price Performance

IRON stock traded down $0.58 during midday trading on Tuesday, reaching $67.06. The company had a trading volume of 38,847 shares, compared to its average volume of 608,015. Disc Medicine has a 1-year low of $40.00 and a 1-year high of $99.50. The company has a debt-to-equity ratio of 0.04, a current ratio of 21.94 and a quick ratio of 21.94. The stock has a 50 day moving average price of $64.79 and a 200-day moving average price of $76.19. The company has a market capitalization of $2.56 billion, a price-to-earnings ratio of -11.29 and a beta of 0.93.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on IRON. Morgan Stanley set a $75.00 price objective on shares of Disc Medicine in a research report on Tuesday, February 17th. Wedbush dropped their price objective on shares of Disc Medicine from $110.00 to $88.00 and set an "outperform" rating on the stock in a research report on Tuesday, February 17th. Wall Street Zen raised shares of Disc Medicine from a "strong sell" rating to a "sell" rating in a research report on Saturday, April 25th. Raymond James Financial reissued a "market perform" rating on shares of Disc Medicine in a research report on Thursday, January 15th. Finally, Stifel Nicolaus dropped their price objective on shares of Disc Medicine from $125.00 to $110.00 and set a "buy" rating on the stock in a research report on Tuesday, February 17th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $104.80.

Insider Transactions at Disc Medicine

In other Disc Medicine news, CEO John D. Quisel sold 13,264 shares of Disc Medicine stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $62.86, for a total value of $833,775.04. Following the transaction, the chief executive officer owned 226,064 shares in the company, valued at $14,210,383.04. The trade was a 5.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Jonathan Yen-Wen Yu sold 3,231 shares of Disc Medicine stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $62.86, for a total value of $203,100.66. Following the completion of the transaction, the chief operating officer owned 54,324 shares in the company, valued at approximately $3,414,806.64. This represents a 5.61% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 59,410 shares of company stock valued at $3,840,013. Company insiders own 3.64% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Persistent Asset Partners Ltd bought a new position in Disc Medicine in the fourth quarter valued at about $141,000. Russell Investments Group Ltd. grew its position in Disc Medicine by 15,137.5% in the third quarter. Russell Investments Group Ltd. now owns 2,438 shares of the company's stock valued at $161,000 after acquiring an additional 2,422 shares during the last quarter. Virtus Investment Advisers LLC grew its position in Disc Medicine by 34.2% in the fourth quarter. Virtus Investment Advisers LLC now owns 2,897 shares of the company's stock valued at $230,000 after acquiring an additional 739 shares during the last quarter. AlphaCentric Advisors LLC bought a new position in Disc Medicine in the fourth quarter valued at about $298,000. Finally, Tower Research Capital LLC TRC grew its position in Disc Medicine by 383.0% in the second quarter. Tower Research Capital LLC TRC now owns 3,975 shares of the company's stock valued at $211,000 after acquiring an additional 3,152 shares during the last quarter. Institutional investors own 83.70% of the company's stock.

Disc Medicine Company Profile

Disc Medicine, Inc NASDAQ: IRON is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.